KeyGene licenses Sequence-Based Genotyping technology to LGC
KeyGene and LGC announced today that they have entered into a service license agreement to expand LGC’s technology portfolio by adding KeyGene’s Sequence-Based Genotyping (SBG) technology.
SBG is recognized in the industry for its broad application for genetic analyses in plants, animals, micro-organisms and model species to characterize genomic diversity and for improvement of traits. Under the agreement, LGC obtains a non-exclusive license for the commercial offering and use of KeyGene's patented SBG technology across all species, including field and vegetable crops, for the global market. The SBG patents protect highly cost-effective methods for identification and scoring of genetic markers, including SBG, Genotyping by Sequencing (GBS), double digest GBS (ddGBS) and related methods. Financial terms of the agreement were not disclosed.
SBG is recognized in the industry for its broad application for genetic analyses in plants, animals, micro-organisms and model species to characterize genomic diversity and for improvement of traits. Under the agreement, LGC obtains a non-exclusive license for the commercial offering and use of KeyGene's patented SBG technology across all species, including field and vegetable crops, for the global market. The SBG patents protect highly cost-effective methods for identification and scoring of genetic markers, including SBG, Genotyping by Sequencing (GBS), double digest GBS (ddGBS) and related methods. Financial terms of the agreement were not disclosed.
"SBG is fully aligned with the needs of translational agriculture and plant breeding programs. We are very pleased with licensing our SBG patent portfolio to LGC, a market-leading genotyping service company", said Michiel van Eijk, CSO of KeyGene. "LGC's excellent reputation and global outreach fits perfectly with our vision for the application and use of the SBG technology and its potential in translational genomics."
“We are excited to be entering into this partnership with a renowned market leader and technology innovator, and see the addition of the SBG methodologies to our service offering as another significant step in serving the complete genotyping and marker discovery needs of our customers”, said Marcus Wills, Strategic Marketing Director, Genomics, LGC.